Retatrutide
Retatrutide (LY3437943) is an investigational peptide developed by Eli Lilly that simultaneously activates three receptors: GLP-1, GIP, and glucagon. Phase 2 trial data showed up to 24% body weight reduction over 48 weeks — making it potentially the most powerful weight loss drug ever tested. Here is everything known about its current status, science, and availability.
⚖️ Legal & Regulatory Status
Last updated: April 15, 2026
Retatrutide is not FDA-approved and is not legally available for prescription in the United States as of April 2026. It is currently in Phase 3 clinical trials conducted by Eli Lilly.
Current status summary:
- ❌ Not FDA-approved — no legal prescription access
- ❌ Cannot be compounded — it is a patented Eli Lilly compound
- 🔬 Phase 3 trials ongoing as of 2026
- ⚠️ Sold on gray market under "research use only" — high legal risk for sellers, source quality unverified
- 📅 Earliest realistic FDA submission: 2026–2027 based on trial timelines
Patent situation: Retatrutide is covered by Eli Lilly's patents. This means even after FDA approval, compounding pharmacy access will not be available unless Lilly faces an official shortage designation — which is how semaglutide/tirzepatide compounding was triggered. This is an important distinction from peptides like BPC-157.
🔬 What the Research Says
Last updated: April 15, 2026
Retatrutide is the most clinically studied of the next-generation weight loss peptides. Unlike semaglutide (GLP-1 only) or tirzepatide (GLP-1 + GIP), retatrutide adds glucagon receptor agonism, which increases energy expenditure on top of appetite suppression.
Phase 2 trial results (published in NEJM, 2023):
- Up to 24.2% mean body weight reduction at the highest dose over 48 weeks
- Significantly outperformed semaglutide and tirzepatide benchmarks in head-to-head analysis
- Improvements in blood pressure, triglycerides, and fasting glucose
- Common side effects: nausea, vomiting, diarrhea (consistent with GLP-1 class)
- Dose-dependent efficacy — higher doses produced more weight loss but more side effects
Mechanism: The triple-agonist approach is significant because glucagon receptor activation increases basal metabolic rate, meaning the body burns more calories at rest — something pure GLP-1 agonists don't do. This may explain the superior weight loss numbers.
Phase 3 trials: Multiple Phase 3 studies are underway as of 2026, examining weight loss, cardiovascular outcomes, and type 2 diabetes management. Results expected 2026–2027.
Key paper: Jastreboff AM et al. "Triple–Hormone-Receptor Agonist Retatrutide for Obesity." NEJM 2023. Available free via PubMed Central.
💬 Community Interest
Last updated: April 15, 2026
Retatrutide generates enormous interest across weight loss, fitness, and biohacking communities. After the Phase 2 data dropped in 2023, it became the most anticipated drug in the obesity space. People who have been on semaglutide or tirzepatide are closely watching its progress as a potential step-up option.
The main community conversations: when will it be approved, what will it cost, will insurance cover it, and whether the gray-market versions being sold online are legitimate (general consensus: extreme caution warranted, as counterfeit GLP-1 peptides have been documented).
There is also significant discussion among clinics and functional medicine practitioners about how to position retatrutide relative to tirzepatide once it gets approved.
📅 Timeline of Changes
Last updated: April 15, 2026
- 2021–2022: Phase 1 trials establish safety and dosing range
- June 2023: Phase 2 results published in New England Journal of Medicine — 24% weight loss headline dominates health media
- Late 2023: Eli Lilly initiates Phase 3 program (TRIUMPH trials)
- 2024: Gray market sales of "retatrutide" proliferate online; FDA issues warning letters
- 2025: Phase 3 trials ongoing; interim data expected
- 2026: Phase 3 completion anticipated; FDA submission possible by end of year
📄 Download Research Brief
Get a comprehensive, printable breakdown of all retatrutide clinical trial data, mechanism of action, comparison to semaglutide and tirzepatide, and expected approval timeline — formatted to share with your doctor or clinic.
Deep-dive research brief available
10 pages covering mechanism of action, research findings, dosing protocols, and safety profile.
Retatrutide Research Brief $9Updated as Phase 3 data and FDA submissions are published. Purchase once, re-download free forever.
PeptideWatch monitors clinical trial registries, FDA announcements, and medical journals daily. This page updates automatically when new information is available. Subscribe to our newsletter to get notified of major developments.